Today is Day 1 of Lung Cancer Awareness Month! 💙 #LCAM Smiling because more patients are living longer with #lungcancer than ever before, thanks to advances in targeted therapies and immunotherapy. 🔬 Still much work ahead: expanding screening, detecting cancer earlier, and developing more effective treatments for all! #LCSM @SylvesterCancer @TheWRP4LC

🇲🇽 Celebrating Día de Muertos in Mexico! A beautiful tradition honoring and remembering loved ones who have passed, celebrating their lives, and welcoming the return of their spirits. A time to remember that those we love are never truly gone as long as we keep their memories alive. ❤️ #DiaDeMuertos #DayOfTheDead #Mexico #Traditions

🏴‍☠️ Ahoy, mateys! Even at the doctor’s office, we’re sailing through Halloween! A little pirate spirit, a lot of team spiri! ☠️🎃 Who says you can’t have fun at a hospital? Happy Halloween from our crew! 🩺🏴‍☠️ #HalloweenAtWork #PirateCrew #DoctorLife #Teamwork @SylvesterCancer

"Make It So” “The first duty of every Starfleet officer is to the truth, whether it's scientific truth, or historical truth, or personal truth!" #RIPPatrickStewart 🖤

Why I voted early 🗳️ because this midterm election matters. Top policy priorities for doctors in the 2026 midterm elections 🩺🇺🇸 1️⃣Medicare reimbursement — Fair, predictable physician payment updates that reflect practice costs. 2️⃣Prior authorization reform — Reduce delays, denials, and administrative burdens. 3️⃣Medicaid access — Protect continuity of coverage and access to providers. 4️⃣Research funding — Sustain NIH, cancer research, and clinical trial funding 5️⃣Affordable healthcare — Improve insurance affordability and provider network access. 6️⃣Prescription drug access — Address medication costs and access to innovative treatment 7️⃣Public health and prevention — Support vaccination, screening, and evidence-based prevention. 8️⃣Patient safety — Promote evidence-based scope-of-practice policies and accountable team-based care. #ASCOAdvocacy #FixPriorAuthorization #NIHFunding #AMA @dadecountymed

🎉 Happy 52nd Birthday, @IASLC! 🎂🎉 For 52 years, the International Association for the Study of Lung Cancer has been bringing together a global community of clinicians, researchers, and advocates to advance science, foster collaboration, and create opportunities for research and innovation. Thank your for all the opportunities and mentoring you have provided me! Here’s to continuing to connect, collaborate, and transform the future of lung cancer care! 🌎🔬💙 #IASLC #LungCancer #LCSM #Research #Collaboration

🚨#ESMO26 and last but not least Top Lung Abstract goes to the new Diva 💃 of #KRASG12C #lungcancer! #KRASCENDO1: Phase III #Divarasib vs sotorasib/adagrasib after prior chemotherapy for #KRASG12C NSCLC 📈 PFS: 9.8 vs 5.7 mo (HR 0.58) 🔥 OS: ~18 vs 12 mo (HR 0.56) 🎯 ORR: 58.4% vs 32.3% ⚠️ Grade 3–4 TRAEs: 24.6% vs 34.5% 🏆This is clearly practice changing with a much better tolerated drug and fewer side effects ( although still GI toxicity) compared to current standard for this high-risk population. 🤔Still some questions about exclusion of untreated brain mets and low number of adagrasib treated pts in control arm #lcsm @KRASKickers

🚨 #ESMO26 | Top Lung Abstracts🫁 PERSEE: Phase 3 🇫🇷 study of pembrolizumab alone vs chemo+pembro for PD-L1-high 🔥 PFS: 16.1 vs 6.9 mo (HR 0.56) 🎯 ORR: 77.5% vs 50.3% ⚠️ Early progression: 5.8% vs 26.5% 📊 OS: 50.2 vs 29.9 mo (HR 0.77; NS) 👉🏽 Maybe more is better for select patients 👉🏽Benefit persisted even with PD-L1 ≥90%—but grade ≥3 TRAEs increased (53.8% vs 19.3%). More disease control but more toxicity. #lcsm #immunotherapy

#ESMO26 🇪🇸 Top Lung Abstracts 🫁 #SAFFRON Phase 3 study of #savolitinib + osimertinib vs. platinum–pemetrexed for MET- driven resistance post osimertinib (N=338) 🎯 MET IHC 3+/ Amp (FISH)>10 🎯 PFS: 7.6 vs 5.4 mo (HR 0.55) 🎯 OS: 17.8 vs 12.9 mo (HR 0.68) 🎯 ORR: 51% vs 27% ⚠️ AEs: Edema & GI toxicity 👉🏽 Clinical Challenge - Although MET resistance post osi can occur 20-30%, it is hard to test for this prospectively in clinic- requires repeat biopsy🔪 #LCSM #LungCancer @EGFRResisters

🚨 #ESMO26 | Top Lung Abstracts 🫁 OptiTROP-Lung04 (Phase III- China only trial) Significant mOS 8.5 mo advantage for sac-TMT, a TROP2 ADC, after EGFR-TKI progression in EGFR-mutant NSCLC🫁 vs chemo! 📊 Median OS: 25.9 vs 17.4 months 🔥 HR 0.69 — 31% lower risk of death ⚠️ AEs- cytopenias, stomatitis, opthal, ILD 👉🏽Competes w Dato-DXd already approved in this EGFR+ population based on Tropion-Lung05, Lung01 👉🏽Global validation and treatment-sequencing questions remain. @EGFRResisters #LCSM #LungCancer #ESMO26

🇪🇸 #ESMO26 | Top Lung Abstracts 🫁 🚨 OPTITROP-Lung06: Phase III trial in PD-L1–negative, driver-negative nonsquamous NSCLC: 🔥 Median PFS: 15.0 vs 5.7 months 📉 HR 0.49 — 51% reduction in risk of progression/death 🎯 DOR: 13.6 vs 6.8 months 📊 12-mo OS: 77.6% vs 66.4% (immature data) ▶️ I wouldn’t call this a “chemo-free” regimen because the toxicity of an ADC is similar to chemo—> but this many be a potential option for this hard to treat PDL1 neg population. ▶️Could this change the 1L landscape? 👀maybe? but I would hope for a bigger survival advantage….data immature … #LungCancer #LCSM #ADC

🇪🇸 #ESMO26 Top Lung Abstracts | SARON 🫁 ☢️In synchronous oligometastatic, driver-negative #NSCLC, adding consolidative RT to systemic therapy improved PFS (13.9 vs 8.9 months; HR 0.64) and local control. ❗But no OS benefit (HR 0.99; p=0.95). Better disease control doesn’t always translate into longer survival! 🔬 #LungCancer #LCSM

@FLASCO_ORG Women’s Cancer Care Symposium panel @jessiemac07 @SylvesterCancer discusses importance of medical teams working together (taking to each other) moving survivorship and supportive care to forefront not an afterthought for women in their cancer journey #cancersurvivorship #WomensHealth

Multi-tasking here.. following game day @univmiami @CanesFootball 🏈 and my son is loving it. always nice when the home team is winning. #gocanes🙌

@FLASCO_ORG Women’s Cancer Care Symposium panel highlighting impact of psychosocial issues, financial toxicity, and caregiving stress for women during their cancer journey with excellent speakers @jessiemac07 @SylvesterCancer Ginger Blackmon, @NCODAorg Ashley Smith @BaptistHealthSF What can medical providers do tomorrow to provide support, build trust❓first step is to listen , ask questions and provide resources

@FLASCO_ORG Women’s Cancer Care Symposium concludes with an important session on Fertility, Family Planning, Chemo side effects, and Mgmt of metabolic & cardiovascular risks for women along their cancer journey chair/ Heather Augustyniak, DNP, APRN, Christelle Ammons, PA, Dr Christy Kesslering #WomensHealth

@FLASCO_ORG Women’s Cancer Care symposium continues with great lectures and case presentations on GYN malignancies- cervical, endometrial and ovarian cancer with Dr Navya Nair @SylvesterCancer Dr. Ina Jain @BaptistHealthSF Dr Scott Jordan @BrowardHealth Michelle Flint, APRN @MountSinaiMiami #GynOnc #WomensHealth

💃🍷 Eating tapas while watching the TOP #lungcancer abstracts roll in from #ESMO26 in Madrid! 🔬 From today’s DeLLphi-305 results with tarlatamab in SCLC to upcoming data on KRAS G12C, EGFR/MET combinations & next-gen ADCs in NSCLC — so much to look forward to! What are YOU most excited about? 👇 #LungCancer #LCSM #ESMO26 🇪🇸 @myESMO

@FLASCO_ORG First Women’s Cancer Care symposium started w great talks, fellow presentations and conversations with academic, community and industry partners about how to address women’s health issues during the cancer journey from diagnosis to survivorship for all cancer types. #WomensHealth #cancersurvivorship @SylvesterCancer

@FLASCO_ORG Women’s Cancer Care Symposium starts with great talks by @COlazagasti and @LaurenGroner @SylvesterCancer on targeted therapies & lung cancer screening and prevention in women. ▶️ recognize rising trend of lung cancer in young women ▶️ role of NGS testing ▶️ strategies to improve lung cancer screening for women ▶️Lung cancer screening as a teachable moment for smoking cessation #lcsm

Meanwhile in Miami 🌴… a dream come true! ✨ Co-chairing @FLASCO_ORG’s first symposium dedicated to Women’s Cancer Care with Heather Augustyniak, APRN. 💜 Moving beyond breast cancer to explore how we can better support women throughout their cancer journey. #WomensCancerCare #FLASCO @SylvesterCancer @BaptistHealthSF

🔥🔥#ESMO26 Top Thoracic Abstracts: #DeLLphi305: Phase III (n=563): Tarlatamab + Durvalumab vs Durvalumab as 1L maintenance after chemo-IO in ES-SCLC Definitely practice changing if we are able to deliver to more pts in the community , moving tarlatamab 1L maintenance ▶️Median OS: 21.1 vs 12.7 months (HR 0.42) 🔥 ▶️12-month OS: 79.4% vs 53.3% ▶️Median PFS: 7.4 vs 1.9 months (HR 0.34) ▶️ORR: 26.4% vs 4.1% ⚠️ Grade ≥3 AEs: 46.8% vs 40.6%; CRS 49.6% (mostly low grade). #lcsm @SclcSMASHERS

Looking forward to the presentation and discussion. #LBA1 Phase 3 INTerpath-001 trial results at #ESMO26 👉🏽The Kaplan-Meir curves don’t always tell the whole story. Side effects, cost, access matter but 👉🏽Its is very exciting that a personalized mRNA technology can be used to control cancer recurrence.

Working from home w cats #CatsofX 🐈

🚨Great news for patients with #EGFRex20ins #lungcancer #Sunvozertinib finally available for dispensation in the US following FDA approval in July 2025. 📌 Approved for previously treated patients based on WU-KONG1B: 🔹 ORR: 46% (95% CI 35–57) 🔹 DoR: 11.1 mo (95% CI 8.2–NE) 📊 In the WU-KONG28 Phase III trial, first-line sunvozertinib vs carbo/pem (n=324) showed: 🔹 ORR: 59% vs 31% 🔹 DoR: 11.2 vs 7.1 mo 🔹 PFS: 10.3 vs 7.5 mo (HR 0.65) 🔹 12-mo PFS: 46% vs 27% 💊 200mg po daily ⚠️ Monitor for ILD/pneumonitis, GI and skin toxicity, ocular toxicity ⚠️ Diarrhea: 75% G3+: 5%) @EGFRResisters

🇧🇷 Obrigada, @IASLC! Excited to travel to São Paulo for #LALCA Nov 12-14 and share perspectives on incorporating ADCs and bispecific antibodies into lung cancer management. 🎙️Scientific Session ES10.03 📅 Nov 13 | 11:45 AM Looking forward to connecting with colleagues across Latin America! 🇧🇷 #LungCancer

5️⃣ days to go for @flasco_voiceofoncology Women’s Cancer Care Conference - a full day of panels dedicated to women’s health across the cancer continuum from diagnosis to survivorship 📆Saturday, October 24, 2026, 8:20 am to 4PM 📍Hotel Colonnade Coral Gables 📖 5.5 CME FREE for @FLASCO_ORG members @sylvestercancer Register at flasco.org/events/cos-flasco…

Finished my favorite run #MIA5K at the Miami Airport runway raising funds for @AmericanCancer @MakingStrides Breast Cancer remains the 2nd leading cause of cancer death among U.S. women, after lung cancer. However, it is the leading cause of cancer death among Hispanic and Black women. 💗Running in honor of my mom who died of breast cancer this year . Raising awareness and raising money for research 💗

Two Boricua thoracic oncologists #RePResentando 🇵🇷 and raising awareness about lung cancer! 💜 Great to connect with my friend and colleague @AnaVManana, now at @panoncology in San Juan, Puerto Rico. ¡Orgullo boricua! 🇵🇷 #LungCancerAwareness #LCSM @OncLive

Toto, I have a feeling we’re not in Miami anymore…

Don’t miss next Saturday 10/24 the first @FLASCO_ORG Clinical Oncology Series dedicated to Women’s Cancer Care – Meeting the Unique Needs of Women with Cancer. I will co-Chair with Heather Augustyniak, DNP, MBA, APRN a full day of panels dedicated to women’s health across the cancer continuum from diagnosis to survivorship 📆Saturday, October 24, 2026, 8:20 am to 4PM 📍Hotel Colonnade Coral Gables 📖 5.5 CME FREE for @FLASCO_ORG members @SylvesterCancer

Heartbroken 💔 to learn this morning of @rachnatshroff’s passing. My deepest condolences to her family and friends. Rachna was a one-of-a-kind physician, leader, and friend. I will always remember the passion she brought to everything she did—from advancing clinical trials and mentoring others to organizing a @ASCO conference or a flash Bollywood mob dance for her best friend’s wedding! I feel incredibly lucky to have known you and to have shared in some of your light. The world was brighter with you in it, Rachna. You will be deeply missed. 🙏 Rest in peace, dear Rachna. 💔

#DCLung26 was not only about learning, but mentoring, too! Great to spend time with Agustina De Rosa, @SylvesterCancer PhD candidate studying EGFR therapy resistance and having the opportunity to introduce her to experts in the field. Grateful to all the colleagues who took the time to share their advice and expertise and encourage the next generation of scientists. #ThoracicOncology #LCSM @LatinasinSTEM #mentoringmatters